Loading organizations...
§ Private Profile · New York City, NY, USA
Riskclick is a technology company.
Riskclick has raised $8.0M across 1 funding round.
Key people at Riskclick.
Riskclick has raised $8.0M in total across 1 funding round.
Risklick develops AI-powered software, Protocol AI, designed to optimize and accelerate the creation of clinical trial protocols and study plans. The platform offers an end-to-end solution that systematically analyzes study design elements, generates multiple scenarios for optimization, and efficiently develops protocols using customized generative AI. This approach leverages a comprehensive database of over 800,000 clinical trials, allowing for faster development timelines and a reduction in protocol amendments, ultimately streamlining the path to market for new treatments.
The company was founded by Dr. Poorya Amini, who serves as CEO, emerging as a spin-off from the University of Bern. Dr. Amini brings a background as a veterinarian with a PhD in pharmacology, which informed the foundational insight that led to Risklick's inception. This insight centered on the critical need to apply advanced artificial intelligence to transform and enhance the efficiency and success rates of clinical trial protocol development within the biopharmaceutical and medical device industries.
Risklick primarily serves biopharmaceutical and medical device companies, equipping experts with tools to refine their research methodology. The company’s vision is to accelerate market access by establishing new benchmarks for precision and excellence in clinical trial design and implementation. By setting these higher standards, Risklick aims to empower its users to deliver innovative therapies to patients more swiftly and reliably, driving forward advancements in healthcare.
Key people at Riskclick.
Riskclick has raised $8.0M in total across 1 funding round.
Riskclick's investors include Amadeus Capital Partners.
# Riskclick: High-Level Overview
Riskclick is a Swiss-based digital health company that develops AI-powered software for clinical trial protocol development.[4] The company's flagship product, Protocol AI, is designed to streamline and optimize the creation of clinical trial protocols and related study documents.[4][5] Riskclick serves pharmaceutical companies, contract research organizations (CROs), and clinical trial sponsors by addressing a critical bottleneck in drug development: the time-consuming and complex process of designing compliant, high-quality clinical trial protocols.
The core problem Riskclick solves is straightforward but significant. Clinical trial protocol development traditionally relies on outdated tools and manual processes, consuming substantial time and resources. Riskclick's AI-driven platform enables companies to shorten protocol development time by 50% while improving regulatory compliance, recruitment rates, and reducing protocol amendments and deviations.[4] By automating and optimizing this foundational step in clinical trials, Riskclick helps accelerate the delivery of new treatments to market.
# Origin Story
Riskclick was founded by Dr. Poorya Amini, whose background uniquely positioned him to identify this opportunity.[4] Amini holds a PhD in pharmacology and trained as a veterinarian before working as a clinical trial project manager at a contract research organization (CRO). This hands-on experience in trial management gave him direct insight into the industry's reliance on outdated tools and the transformative potential of AI to address these inefficiencies. Recognizing this gap, Amini founded Risklick to create Protocol AI and drive innovation in clinical trial protocol development.
The company's early journey was marked by skepticism. Investors initially doubted Riskclick's viability, arguing that large pharmaceutical corporations would develop competing solutions in-house, making an independent platform unnecessary.[4] However, Amini remained committed to the vision. The validation came when some of those same large corporations eventually adopted Riskclick's platform and abandoned their internal solutions—a testament to the company's deep expertise and superior execution.[4]
# Core Differentiators
# Role in the Broader Tech Landscape
Riskclick operates at the intersection of two powerful trends: AI-driven automation in regulated industries and digital transformation in life sciences. The pharmaceutical industry faces mounting pressure to accelerate drug development timelines while maintaining regulatory compliance—a challenge that has only intensified as development costs and timelines have grown. Clinical trial protocol development, a foundational step that directly impacts overall trial duration and success rates, represents an ideal target for AI optimization.
The timing is particularly favorable. Regulatory bodies are increasingly receptive to AI-assisted tools in drug development, and the industry has accumulated sufficient historical trial data to train effective AI models. Riskclick's success also signals broader market validation: the fact that major pharmaceutical corporations chose to adopt an external platform over internal solutions demonstrates that specialized, focused AI tools can outcompete generalist approaches even among well-resourced incumbents.
By establishing best practices and paving the way for the market in clinical trial AI, Riskclick is not only building a company but shaping how the entire industry approaches protocol development.[4]
# Quick Take & Future Outlook
Riskclick is positioned to become a critical infrastructure layer in pharmaceutical R&D. As clinical trial timelines remain a bottleneck in drug development and regulatory pressure to accelerate treatments intensifies, demand for Protocol AI should grow substantially. The company's early mover status, combined with demonstrated adoption by major pharmaceutical players, suggests strong competitive moats.
The key challenge ahead lies in scaling while maintaining data security and privacy compliance—critical requirements in regulated healthcare.[4] As Riskclick expands its user base and integrates with broader clinical trial ecosystems, the company will need to deepen its platform capabilities and potentially expand into adjacent areas of clinical development.
Looking forward, Riskclick exemplifies how specialized AI tools can unlock value in entrenched, regulated industries by solving specific, high-impact problems with deep domain expertise. The company's trajectory will likely influence how other life sciences software vendors approach AI integration, making Riskclick a bellwether for AI adoption in pharmaceutical development.
Riskclick has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Series C in May 2005.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2005 | $8M Series C | — | Amadeus Capital Partners | Announced |
